Novartis to Wind Down MorphoSys Locations

ZURICH (Reuters) – Swiss pharmaceutical group Novartis (SIX:NOVN) announced on Thursday it will wind down MorphoSys sites in Germany and the United States, impacting 330 jobs.

Novartis acquired MorphoSys earlier this year, and the decision is part of an evaluation of its organizational structure influenced by evolving research and development (R&D) strategies.

A company spokesperson stated, "We have communicated our intention to exit the MorphoSys sites in Munich and in Boston by the end of 2025," following a report from WirtschaftsWoche magazine.

"Approximately 330 roles were impacted, and all individuals were already communicated in mid-November," the spokesperson added, affirming the company's commitment to support affected employees.

(Note: $1 = 0.9610 euros)